GlaxoSmithKline’s new antibody‑drug conjugate, Mo‑Rez, showed a 62 % objective response in ovarian cancer and 67 % in endometrial cancer during a Phase 2 trial. Those figures dwarf the 41 % median response of U.S. FDA‑approved agents between 2006‑2018, offering a sharper hit rate for hard‑to‑treat tumours for patients worldwide and potentially boosting GSK's oncology portfolio and future sales projections significantly.

Mo‑Rez is a next‑generation antibody‑drug conjugate that delivers chemotherapy directly to cancer cells, reducing systemic toxicity. GSK, which acquired global rights from Hansoh Pharma in 2023, will advance the drug into five Phase 3 studies this year, positioning it for a possible launch once regulatory approval follows in the coming years and boosting share price growth.

After shedding its oncology division in 2014, GSK has rebuilt the segment under former CEO Emma Walmsley, now recording £2 bn in sales last year—a 43 % jump. The Mo‑Rez rollout could add an estimated £2 bn in peak annual revenue if approvals materialise, aligning with the company’s £40 bn 2031 sales ambition and supporting future growth targets globally.

Mo‑Rez marks GSK’s second partnership with Hansoh, which also co‑develops a lung‑cancer antibody‑drug conjugate. The deal follows a $12 bn agreement with China’s Hengrui Pharma to co‑develop up to 12 drugs. These collaborations underscore a broader strategy of sourcing best‑in‑class technologies from Chinese innovators to diversify GSK’s pipeline and strengthen its global presence in oncology while reducing development risks.